2014


To access this material please log in or register

Register Authorize
2014/№2

The place of angiotensin-converting enzyme inhibitors and angiotensin II antagonists in the treatment of hypertrophic cardiomyopathy

Krylova N.S., Khashieva F.M., Demkina A.E., Poteshkina N.G.

Keywords: angiotensin II receptor antagonists, HCMP, ACE inhibitors, treatment

DOI: 10.18087/rhfj.2014.2.1906

Beta-blockers and non-hydropyridine calcium antagonists (Ca2+A, verapamil) are drugs of choice for the treatment of hypertrophic cardiomyopathy (HCMP). In the guidelines on therapy for HCMP (ACCF / AHA, 2011), administration of ACEI for nonobstructive HCMP with normal LV systolic function corresponds to IIb C class of evidence-based medicine, and only in impaired LV systolic function (LV EF <50 %) – to IB class. In some studies, ACEI or AAII treatment improved the clinical condition and reduced myocardial hypertrophy in patients with non-obstructive HCMP. However ACEIs and AAII may impair prognosis in patients with obstructive HCMP by decreasing preload and increasing obstruction. The limited number of reports on beneficial effects of long-acting ACEIs or AAII in obstructive HCMP and the absence of consensus on their efficacy and safety justifies the need for further studies in this field.
  1. Maron BJ, Towbin JA, Thiene G et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113 (14):1807–1816.
  2. Gersh BJ, Maron BJ, Bonow RO et al. 2011 ACCF / AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardio­logy Foundation / American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58 (25):e212–260.
  3. Force T, Bonow RO, Houser SR et al. Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. Circulation. 2010 Sep 14;122 (11):1130–3.
  4. Tian T, Liu Y, Zhou X, Song L. Progress in the Molecular Genetics of Hypertrophic Cardiomyopathy: A Mini-Review. Gerontology. 2013;59 (3):199–205.
  5. Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol. 2012 Aug 21;60 (8):705–15.
  6. Шостак Н. А., Якушин С. С., Филиппов Е. В. Кардиомиопатии. Кардиология. Национальное руководство / Под ред. Ю. Н. Беленкова, Р. Г. Оганова. –М.: ГОЭТАР-Медиа, 2009. – с. 360–365.
  7. Беленков Ю. И., Привалова Е. В., Каплунова В. Ю. Гипертрофи­ческая кардиомиопатия: руководство для врачей. – М.: ГОЭТАР-­Медиа, 2011. – 392с.
  8. O'Mahony C, Tome-Esteban M, Lambiase PD. et al. A validation study of the 2003 ACC / ESC and 2011 ACCF / AHA risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy. Heart. 2013 Apr;99 (8):534–41.
  9. Maron BJ. Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy. Circulation. 2010 Jan 26;121 (3):445–56.
  10. Шапошник И. И., Богданов Д. В. Гипертрофическая кардиомиопатия. – М:. Медпрактика-М, 2008. –c.19–20.
  11. Maron B. J. Hypertrophic cardiomyopathy. Braunwald's heart disease: a textbook of cardiovascular medicine. – Elsevier Inc. 2011. –p. 1582–94.
  12. Моисеев В. С., Киякбаев Г. К. Кардиомиопатии и миокардиты. –М.: ГОЭТАР-Медиа, 2011. – 352с.
  13. Spirito P, Seidman CE, McKenna WJ et al. The management of hypertrophic cardiomyopathy. N Engl J Med. 1997;336 (11):775–785.
  14. Якушин С. С., Филиппов Е. В. Гипертрофическая кардиомиопатия и сочетанная кардиологическая патология: особенности диагностики и лечения. Архив внутренней медицины. 2011;1:11–14.
  15. Aslam F, Haque A, Foody J et al. The frequency and functional impact of overlapping hypertension on hypertrophic cardiomyopathy: a single-center experience. J Clin Hypertens (Greenwich). 2010 Apr;12 (4):240–5.
  16. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33 (14):1787–1847.
  17. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH / ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31 (7):1281–1357.
  18. Montalescot G, Sechtem U, Achenbach S et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34 (38):2949–3003.
  19. Емелина Е. И., Гендлин Г. Е. Престариум а в монотерапии артериальной гипертензии. Лечебное дело. 2011;4:35–42.
  20. Чернявская Т. К., Волчкова Е. В. ИАПФ в реальной клинической практике: неравенство равных. Врач. 2013;5:55–59.
  21. Хабарова Н. В. Оценка эффективности дифференцированного лечения ГКМП на основе длительного проспективного наблюдения. Автореф. канд. мед. наук. – Москва, 1994.
  22. Гуревич М. А. Принципы консервативной терапии гипертрофической кардиомиопатии. Consilium medicum. 2011;1 (10).
  23. Penicka M, Gregor P, Kerekes R et al. Candesartan use in Hypertrophic And Non-obstructive Cardiomyopathy Estate (CHANCE) Study Investigators. 2009 Jan;11 (1):35–41.
  24. Topol EJ, Traill TA, Fortuin NJ. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med. 1985;312 (5):277–283.
  25. Терещенко С. Н., Скворцов А. А., Нарусов О. Ю. и др. Результаты изучения проблемы «Заболевания миокарда и сердечная недостаточность» в Институте клинической кардиологии им. А. Л. Мясникова. Кардиологический вестник. 2010: V (XVII) 1:33–38.
  26. Yamazaki T, Suzuki J, Shimamoto R et al. A new therapeutic stra­tegy for hypertrophic nonobstructive cardiomyopathy in humans. A randomized and prospective study with an Angiotensin II receptor blocker. Int Heart J. 2007 Nov;48 (6):715–24.
  27. Araujo A. Q, Arteaga E, Ianni B. M et al. Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy. Am J Cardiol. 2005 Dec 1;96 (11):1563–7.
  28. O'Hanlon R, Grasso A, Roughton M et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 2010;56 (11):867–74.
  29. Kawano H, Toda G, Nakamizo R et al. Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy. Circ J. 2005 Oct;69 (10):1244–8.
  30. Смирнова М. Д., Агеев Ф. Т. Опыт использования ирбесартана в терапии необструктивной гипертрофической кардиомиопатии. Клиническое наблюдение. 2007;4 (2):83–88.
  31. Габитов С. З. Случай гипертонической гипертрофической кардиомиопатии обструктивного типа. Практическая медицина, 2011;3–1 (50):44–46.
Krylova N.S., Khashieva F.M., Demkina A.E. et al. The place of angiotensin-converting enzyme inhibitors and angiotensin II antagonists in the treatment of hypertrophic cardiomyopathy. Russian Heart Failure Journal. 2014;83 (2):95–100

To access this material please log in or register

Register Authorize
Ru En